{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:05:53Z","timestamp":1793203553516,"version":"4.5.0"},"reference-count":23,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To evaluate the effect of tirzepatide on body weight, glycaemic control, insulin requirements, continuous glucose monitoring (CGM) metrics and cardiorenal parameters in adults with Type 1 diabetes (T1D) and overweight or obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      In this retrospective matched cohort study, adults with T1D, BMI\u2009\u2265\u200927\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , CGM use and available baseline and follow\u2010up electronic medical record data from Royal North Shore Hospital and the Northern Sydney Endocrine Centre between 2020 and 2025 were included. Twenty\u2010three adults treated with tirzepatide were identified and propensity score\u2010matched to 23 control participants. Primary outcomes included changes in percentage change in body weight, HbA1c, total daily insulin dose and CGM\u2010derived metrics from baseline to follow\u2010up. Exploratory outcomes included changes in blood pressure and biochemical markers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean follow\u2010up duration in the tirzepatide and control groups were 28 and 31\u2009weeks, respectively. The most common dose of tirzepatide was 5\u2009mg\/week (52.2% participants). Compared with controls, tirzepatide was associated with greater reductions in body weight (\u221210.01%\u2009\u00b1\u20094.74% vs. +0.69%\u2009\u00b1\u20093.77%, adj\u2010\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and total daily insulin dose (\u221221.82\u2009\u00b1\u200916.30 vs. +5.62\u2009\u00b1\u200911.63\u2009U\/day; adj\u2010\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002). From baseline to end\u2010of\u2010study, tirzepatide was associated with a reduction in glucose management indicator, glucose SD and daily carbohydrate intake. Other CGM, blood pressure, lipid, hepatic and renal outcomes did not differ.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In adults with T1D and overweight or obesity, adjunctive tirzepatide treatment was associated with clinically meaningful reductions in percentage body weight and insulin requirements. Larger prospective studies are needed to confirm efficacy, ensure safety and assess broader cardiometabolic effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.71063","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:53:44Z","timestamp":1782964424000},"page":"8560-8567","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Tirzepatide Is Associated With Improved Metabolic Outcomes in People With Type 1 Diabetes and Overweight or Obesity: A Retrospective Cohort Study"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5728-6054","authenticated-orcid":false,"given":"Amanda R.","family":"Purcell","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Health University of Sydney  Sydney New South Wales Australia"},{"name":"Kolling Institute  St Leonards New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3795-2254","authenticated-orcid":false,"given":"Matilda S. G.","family":"Longfield","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health University of Sydney  Sydney New South Wales Australia"},{"name":"Kolling Institute  St Leonards New South Wales Australia"},{"name":"Department of Diabetes, Metabolism and Endocrinology Royal North Shore Hospital  St Leonards New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natassia","family":"Rodrigo","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health University of Sydney  Sydney New South Wales Australia"},{"name":"Kolling Institute  St Leonards New South Wales Australia"},{"name":"Department of Diabetes, Metabolism and Endocrinology Royal North Shore Hospital  St Leonards New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Glastras","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health University of Sydney  Sydney New South Wales Australia"},{"name":"Kolling Institute  St Leonards New South Wales Australia"},{"name":"Department of Diabetes, Metabolism and Endocrinology Royal North Shore Hospital  St Leonards New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0384"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108973"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcdhc.2025.1670312"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.70060"},{"key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.2147\/DMSO.S240903","article-title":"SGLT2 Inhibitors in the Management of Type 1 Diabetes (T1D): An Update on Current Evidence and Recommendations","volume":"16","author":"Maffei P.","year":"2023","journal-title":"Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep44128"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70188"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01604-7"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70143"},{"issue":"5","key":"e_1_2_10_12_1","article-title":"Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond","volume":"15","author":"Dutta P.","year":"2023","journal-title":"Cureus"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2023.08.012"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2024.0481"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-2379"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/19322968231223991"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/cd22-0060"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102782"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci25-0015"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.2.140"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00246-1"},{"issue":"3","key":"e_1_2_10_22_1","first-page":"193","article-title":"Glucose Control and Continuous Glucose Monitoring Metrics During 12 Months of Treatment With Tirzepatide in Overweight or Obese Patients With Type 1 Diabetes","volume":"28","author":"Akturk H. K.","year":"2026","journal-title":"Diabetes Technology & Therapeutics"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04274-0"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40200-024-01412-8"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71063","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.71063","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71063","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T08:52:19Z","timestamp":1786092739000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.71063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/dom.71063"],"URL":"https:\/\/doi.org\/10.1111\/dom.71063","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.71063\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71063\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71063\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71063\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71063\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71063\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71063\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71063\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.71063\/v1\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"2026-04-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}